Development History
Developed M1-c6v1
2016
Completed the development of the oncolytic virus M1-c6v1
Established pilot technique
2017
Established the pilot technique of oncolytic virus M1-c6v1
M1–VCP inhibitor combination therapy
2017
Enhances specificity, cytotoxicity or immune-stimulating potential of the virus. Accumulation of unfolded proteins during virus replication leads to a transcriptional/ translational response known as the unfolded protein response (UPR), which might counteract the antitumor effect of the oncolytic virus.
CMC, non-clinical and clinical of M1-c6v1 granted
2018
The CMC, non-clinical and clinical of M1-c6v1 was granted by the projects titled 13th Five-Year Major New Drug Creation Project, Leading Team for entrepreneurship in Guangzhou, Guangdong Province and Pioneering talents project of Guangzhou Development Zone, Guangdong Province.
Applied for clinical trials of M1-c6v1 in China, United States and Australia
2019
Virotech starts the clinical trial application of oncolytic virus M1-c6v1 in China, United States and Australia.
ZAP detection kit registered as Class I Medical Device
2020
Zinc finger antiviral protein (ZAP) detection kit (IHC) for the companion diagnostics of oncolytic virus M1 is registered as a Class I Medical Device.
M1 targets ZAP-defective human cancers
2021
Zinc-finger antiviral protein (ZAP) Deficiency Is Necessary for the High Tumor Specificity of M1. Tumor-Selective Replication of M1 Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in Cancer Cells.
|
|
Contact Us
Virotech is located in Guangzhou high-tech industrial development zone science city
Guangzhou International Business Incubator G District 416--428,No.3, Langyue Rd, Science Park
+86 020-32030745
virotech@virot.cn
Name
*
Phone
*
E-mail
*
Content
*
Submit